Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients

Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients have?

Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients has 198 citations in the OpenAlex counts ScholarIQ stores.

When was Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients published?

Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients has 2009 year in the ScholarIQ index.

What is the open-access status of Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients?

Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients has bronze oa status in the ScholarIQ index.

What is the DOI of Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients?

The DOI for Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients is on the source record.

What is the PMID of Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients?

The PMID for Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients is on the source record.

What is the OpenAlex record for Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients?

The OpenAlex for Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients is on the source record.